Citi Pharma (KAR:CPHL) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KAR:CPHL Citi Pharma Ltd KAR:CPHL
5 GF Score
Price ₨75.38
GF Value ₨49.30
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is Citi Pharma Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

KAR:CPHL
5GF Score
Citi Pharma Ltd KAR:CPHL
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Citi Pharma (KAR:CPHL) Overvalued in 2026?

Based on GuruFocus' analysis, Citi Pharma stock appears to be overvalued. The current stock price of ₨75.38 is trading 52.9% above its estimated GF Value™ of ₨49.30. GuruFocus considers Citi Pharma to be Significantly Overvalued.

Key valuation signals for KAR:CPHL:

  • Dividends Received:
  • GF Value™: ₨49.30 vs. price of ₨75.38 (52.9% above fair value)
  • GF Score™: 5/100 with 1 warning sign

No single metric tells the full story. See the KAR:CPHL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Citi Pharma Business Description

Address 588 Q Block, M.A., Johar Town, Lahore, PB, PAK
Citi Pharma Ltd is engaged in the manufacturing and sale of pharmaceuticals, medical chemicals and botanical products. Its product portfolio includes API segment, Formulation segment, Cephalosporin formulation, and Nutraceuticals. The API segment includes Paracetamol, Penicillin/Amoxicillin, Levofloxacin, Cefixime/Cephalosporin, Ciprofloxacin, Cephradine, Norfloxacin, Aspirin, and Ibuprofen.
5GF Score

Get the complete analysis for KAR:CPHL

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₨75.38
Price
₨49.30
GF Value